Catalytic Activity Is Not Required for Secreted PCSK9 to Reduce Low Density Lipoprotein Receptors in HepG2 Cells*

Proprotein convertase subtilisin/kexin type 9 (PCSK9), a member of the proteinase K subfamily of subtilases, promotes internalization and degradation of low density lipoprotein receptors (LDLRs) after binding the receptor on the surface of hepatocytes. PCSK9 has autocatalytic activity that releases the prodomain at the N terminus of the protein. The prodomain remains tightly associated with the catalytic domain as the complex transits the secretory pathway. It is not known whether enzymatic activity is required for the LDLR-reducing effects of PCSK9. Here we expressed the prodomain together with a catalytically inactive protease domain in cells and purified the protein from the medium. The ability of the catalytically inactive PCSK9 to bind and degrade LDLRs when added to culture medium of human hepatoma HepG2 cells at physiological concentrations was similar to that seen using wild-type protein. Similarly, a catalytic-dead version of a gain-of-function mutant, PCSK9(D374Y), showed no loss of activity compared with a catalytically active counterpart; both proteins displayed ∼10-fold increased activity in degradation of cell surface LDLRs compared with wild-type PCSK9. We conclude that the ability of PCSK9 to degrade LDLRs is independent of catalytic activity and suggest that PCSK9 functions as a chaperone to prevent LDLR recycling and/or to target LDLRs for lysosomal degradation.

[1]  D A Agard,et al.  The role of pro regions in protein folding. , 1993, Current opinion in cell biology.

[2]  Alexander Pertsemlidis,et al.  Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9 , 2005, Nature Genetics.

[3]  R. Hammer,et al.  Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[4]  J. Breslow,et al.  Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[5]  K Nakayama,et al.  Furin: a mammalian subtilisin/Kex2p-like endoprotease involved in processing of a wide variety of precursor proteins. , 1997, The Biochemical journal.

[6]  H. Khorana,et al.  Structure and function in rhodopsin: high level expression of a synthetic bovine opsin gene and its mutants in stable mammalian cell lines. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[7]  N. Seidah,et al.  Wild-type PCSK9 inhibits LDL clearance but does not affect apoB-containing lipoprotein production in mouse and cultured cells Published, JLR Papers in Press, March 1, 2005. DOI 10.1194/jlr.M400396-JLR200 , 2005, Journal of Lipid Research.

[8]  G. Thomas,et al.  The Ordered and Compartment-specific Autoproteolytic Removal of the Furin Intramolecular Chaperone Is Required for Enzyme Activation* , 2002, The Journal of Biological Chemistry.

[9]  Jonathan C. Cohen,et al.  Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. , 2006, The New England journal of medicine.

[10]  Jonathan C. Cohen,et al.  Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote. , 2006, American journal of human genetics.

[11]  Jay D. Horton,et al.  Post-transcriptional Regulation of Low Density Lipoprotein Receptor Protein by Proprotein Convertase Subtilisin/Kexin Type 9a in Mouse Liver* , 2004, Journal of Biological Chemistry.

[12]  Annik Prat,et al.  The Cellular Trafficking of the Secretory Proprotein Convertase PCSK9 and Its Dependence on the LDLR , 2007, Traffic.

[13]  A. Prat,et al.  NARC-1/PCSK9 and Its Natural Mutants , 2004, Journal of Biological Chemistry.

[14]  Jonathan C. Cohen,et al.  Binding of Proprotein Convertase Subtilisin/Kexin Type 9 to Epidermal Growth Factor-like Repeat A of Low Density Lipoprotein Receptor Decreases Receptor Recycling and Increases Degradation* , 2007, Journal of Biological Chemistry.

[15]  J. Weissenbach,et al.  Mutations in PCSK9 cause autosomal dominant hypercholesterolemia , 2003, Nature Genetics.

[16]  T. Ranheim,et al.  Effect of mutations in the PCSK9 gene on the cell surface LDL receptors. , 2006, Human molecular genetics.

[17]  A. Prat,et al.  The proprotein convertases and their implication in sterol and/or lipid metabolism , 2006, Biological chemistry.

[18]  E. Fisher,et al.  Overexpression of PCSK9 accelerates the degradation of the LDLR in a post-endoplasmic reticulum compartment. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[19]  N. Seidah,et al.  Comparative biosynthesis, covalent post-translational modifications and efficiency of prosegment cleavage of the prohormone convertases PC1 and PC2: glycosylation, sulphation and identification of the intracellular site of prosegment cleavage of PC1 and PC2. , 1993, The Biochemical journal.

[20]  C. Slaughter,et al.  Secreted Site-1 Protease Cleaves Peptides Corresponding to Luminal Loop of Sterol Regulatory Element-binding Proteins* , 1999, The Journal of Biological Chemistry.

[21]  A. Prat,et al.  The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): Liver regeneration and neuronal differentiation , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[22]  Xiayang Qiu,et al.  Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia , 2007, Nature Structural &Molecular Biology.

[23]  B. Ozenberger,et al.  Functional characterization of Narc 1, a novel proteinase related to proteinase K. , 2003, Archives of biochemistry and biophysics.

[24]  G. Thomas,et al.  Intracellular trafficking and activation of the furin proprotein convertase: localization to the TGN and recycling from the cell surface. , 1994, The EMBO journal.

[25]  R. Hammer,et al.  Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice. , 2006, The Journal of clinical investigation.

[26]  N. Seidah,et al.  Eukaryotic protein processing: endoproteolysis of precursor proteins. , 1997, Current opinion in biotechnology.